- Real-world data from 40,000 patients demonstrates improved vision outcomes.
- Extended dosing intervals potentially reduce treatment burden.
- Comprehensive safety and efficacy data across multiple retinal conditions.
Regeneron Pharmaceuticals (REGN, Financial) will present 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, including eight oral presentations focusing on EYLEA HD® (aflibercept) Injection 8 mg. The presentations will reveal initial real-world data from nearly 40,000 patients, confirming the improved vision and longer dosing intervals achieved in clinical practice for conditions like wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
The key highlights from the presentations include analyses of treatment outcomes for patients who are either treatment-naive or have switched from other therapies. The data signifies EYLEA HD's value in everyday clinical settings, offering clinical benefits over competitors like faricimab through network meta-analyses that evaluate efficacy and economic benefits over a span of three years.
Common adverse reactions reported in over 3% of cases include cataracts, conjunctival hemorrhage, increased intraocular pressure, ocular discomfort, and blurred vision, among others. This aligns with the safety profile observed in clinical trials.
These findings reinforce Regeneron's strategic market positioning, leveraging EYLEA HD's extended dosing intervals and vision improvement as competitive differentiators. These aspects highlight the potential of EYLEA HD to become the new standard of care in managing serious retinal conditions such as wAMD, DME, and diabetic retinopathy (DR).
